Brokerages expect Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) to report ($0.10) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Ekso Bionics’ earnings. Ekso Bionics posted earnings per share of ($0.41) during the same quarter last year, which would indicate a positive year-over-year growth rate of 75.6%. The firm is expected to announce its next quarterly earnings report on Tuesday, March 6th.
According to Zacks, analysts expect that Ekso Bionics will report full year earnings of ($0.81) per share for the current fiscal year. For the next fiscal year, analysts forecast that the company will report earnings of ($0.35) per share. Zacks’ earnings per share calculations are an average based on a survey of research firms that follow Ekso Bionics.
Ekso Bionics (NASDAQ:EKSO) last posted its quarterly earnings results on Wednesday, November 8th. The company reported ($0.18) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.05). The business had revenue of $1.60 million for the quarter, compared to the consensus estimate of $2.40 million. Ekso Bionics had a negative return on equity of 323.00% and a negative net margin of 343.53%.
Shares of Ekso Bionics (EKSO) opened at $1.42 on Monday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 5.73 and a current ratio of 6.09. The firm has a market cap of $85.06, a P/E ratio of -1.53 and a beta of 1.47. Ekso Bionics has a 12 month low of $0.99 and a 12 month high of $4.77.
In other Ekso Bionics news, insider Russ Angold sold 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 22nd. The shares were sold at an average price of $3.51, for a total value of $175,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 3.32% of the stock is currently owned by corporate insiders.
A number of large investors have recently modified their holdings of EKSO. Intellectus Partners LLC boosted its holdings in shares of Ekso Bionics by 5.3% in the second quarter. Intellectus Partners LLC now owns 105,294 shares of the company’s stock valued at $244,000 after buying an additional 5,294 shares during the period. Carl Domino Inc boosted its holdings in shares of Ekso Bionics by 125.2% in the third quarter. Carl Domino Inc now owns 184,788 shares of the company’s stock valued at $224,000 after buying an additional 102,734 shares during the period. National Planning Corp boosted its holdings in shares of Ekso Bionics by 122.2% in the third quarter. National Planning Corp now owns 520,942 shares of the company’s stock valued at $620,000 after buying an additional 286,492 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in shares of Ekso Bionics by 32.9% in the second quarter. Vanguard Group Inc. now owns 711,082 shares of the company’s stock valued at $1,650,000 after buying an additional 176,197 shares during the period. 6.18% of the stock is owned by hedge funds and other institutional investors.
WARNING: “Ekso Bionics Holdings, Inc. (EKSO) Expected to Post Earnings of -$0.10 Per Share” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.americanbankingnews.com/2018/02/05/ekso-bionics-holdings-inc-ekso-expected-to-post-earnings-of-0-10-per-share.html.
About Ekso Bionics
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.